abrdn plc Invests $3.73 Million in Xencor, Inc. (NASDAQ:XNCR)

abrdn plc bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 175,520 shares of the biopharmaceutical company's stock, valued at approximately $3,726,000. abrdn plc owned 0.29% of Xencor as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Primecap Management Co. CA increased its position in shares of Xencor by 5.6% during the third quarter. Primecap Management Co. CA now owns 8,184,206 shares of the biopharmaceutical company's stock worth $164,912,000 after purchasing an additional 433,354 shares in the last quarter. Armistice Capital LLC boosted its holdings in Xencor by 65.7% in the third quarter. Armistice Capital LLC now owns 1,478,000 shares of the biopharmaceutical company's stock valued at $29,782,000 after purchasing an additional 586,000 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Xencor by 4.6% in the third quarter. Invesco Ltd. now owns 555,809 shares of the biopharmaceutical company's stock valued at $11,200,000 after acquiring an additional 24,303 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Xencor by 2.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 488,447 shares of the biopharmaceutical company's stock valued at $9,842,000 after acquiring an additional 10,346 shares during the period. Finally, Hudson Bay Capital Management LP lifted its holdings in shares of Xencor by 144.7% during the third quarter. Hudson Bay Capital Management LP now owns 232,500 shares of the biopharmaceutical company's stock worth $4,685,000 after purchasing an additional 137,500 shares during the period.

Insider Activity

In related news, CEO Bassil I. Dahiyat sold 2,741 shares of Xencor stock in a transaction on Monday, March 11th. The stock was sold at an average price of $23.50, for a total transaction of $64,413.50. Following the completion of the sale, the chief executive officer now directly owns 351,894 shares of the company's stock, valued at $8,269,509. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Bassil I. Dahiyat sold 2,741 shares of Xencor stock in a transaction on Monday, March 11th. The stock was sold at an average price of $23.50, for a total transaction of $64,413.50. Following the completion of the sale, the chief executive officer now directly owns 351,894 shares of the company's stock, valued at $8,269,509. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP John R. Desjarlais sold 54,108 shares of Xencor stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total value of $1,048,613.04. Following the sale, the vice president now directly owns 161,675 shares of the company's stock, valued at $3,133,261.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,351 shares of company stock valued at $2,152,417. Company insiders own 4.97% of the company's stock.

Analyst Ratings Changes

XNCR has been the subject of a number of research analyst reports. BTIG Research dropped their price target on Xencor from $56.00 to $38.00 and set a "buy" rating for the company in a research report on Tuesday, April 16th. StockNews.com upgraded Xencor from a "sell" rating to a "hold" rating in a research report on Saturday, March 9th. BMO Capital Markets cut their price objective on Xencor from $38.00 to $34.00 and set an "outperform" rating for the company in a report on Wednesday, February 28th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $32.00 target price on shares of Xencor in a report on Wednesday, February 28th. Finally, Piper Sandler reissued a "neutral" rating and issued a $24.00 price objective (down from $37.00) on shares of Xencor in a research note on Wednesday, February 28th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $36.00.

Xencor Price Performance

XNCR traded up $1.09 during trading on Monday, hitting $21.07. The company's stock had a trading volume of 735,801 shares, compared to its average volume of 686,474. The firm's 50 day moving average price is $21.96 and its two-hundred day moving average price is $20.38. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 0.02. Xencor, Inc. has a 12 month low of $16.49 and a 12 month high of $28.96. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -10.03 and a beta of 0.76.

Xencor (NASDAQ:XNCR - Get Free Report) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of $0.36 by ($0.67). The firm had revenue of $44.70 million during the quarter, compared to analyst estimates of $77.63 million. Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. The firm's quarterly revenue was up 106.9% on a year-over-year basis. During the same period last year, the business posted ($0.20) earnings per share. Sell-side analysts forecast that Xencor, Inc. will post -3.25 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.